during the promptly evolving field of oncology research, precise and efficient mutation screening is crucial for establishing targeted therapies. The KRAS providers Platform plays a pivotal function During this landscape by providing in depth remedies for KRAS mutation profiling and analysis. KRAS mutations, present in roughly ninety five% of RAS-c